Ozempic Lawsuit 2026: MDL Updates, Who Qualifies, and What Settlements May Pay

QUICK ANSWER:

What Is the Ozempic Lawsuit?

The Ozempic lawsuit refers to thousands of personal injury lawsuits filed against Novo Nordisk, the manufacturer of Ozempic (semaglutide), by patients who allege the drug caused severe gastrointestinal injuries, including gastroparesis (stomach paralysis), and vision loss (NAION), without adequate warning.

Key facts at a glance:

• As of April 2026, more than 3,546 cases are pending in MDL No. 3094 in the Eastern District of Pennsylvania

• A separate MDL — MDL No. 3163 — covers NAION (vision loss) claims related to semaglutide

• Eligible claimants are individuals who used Ozempic, Wegovy, or Rybelsus and suffered serious gastrointestinal or ophthalmic injuries

• No global settlement has been reached as of the date of this publication; bellwether trials are expected to shape early resolution timelines

• The core legal theory is failure to warn, the allegation that Novo Nordisk knew or should have known about these risks and failed to disclose them on the drug label adequately

Picture this. A person with Type 2 diabetes starts taking Ozempic at their doctor's recommendation. The drug works beautifully at first, blood sugar stabilizes, weight drops. Then, months later, the nausea that started as a mild side effect turns into something unbearable. Food stops moving through the stomach. Vomiting becomes daily. A gastroenterologist runs a gastric emptying study and delivers a diagnosis no one expected: gastroparesis, and permanent stomach paralysis.

That scenario is not rare. Attorneys across the country are now representing thousands of patients who allege Novo Nordisk failed to warn them, and their doctors, about exactly these kinds of risks.

The Ozempic lawsuit has become one of the most significant pharmaceutical mass torts of the decade. With over 3,546 pending cases consolidated in MDL No. 3094 in the Eastern District of Pennsylvania, and a second MDL forming around vision loss claims, the litigation is still in its early stages, but it is moving fast.

Here is what you need to know: who is suing, why, what injuries are covered, how much settlements might be worth, and how to determine if you qualify to file a claim.

What Is the Ozempic Lawsuit? (Overview)

The Ozempic lawsuit is a product liability action filed against Novo Nordisk, the Danish pharmaceutical company that manufactures Ozempic (semaglutide), Wegovy, and Rybelsus.

At its core, these lawsuits allege that Novo Nordisk knew, or reasonably should have known, that semaglutide carries a significant risk of causing severe gastrointestinal conditions, including gastroparesis, ileus, and intestinal obstruction, and that the company failed to adequately warn patients and healthcare providers about these risks on the drug's official label.

This is a legal theory known as failure to warn, one of the most common forms of pharmaceutical product liability litigation in the United States. Plaintiffs are not necessarily arguing the drug should never have been approved. They are arguing that the known risks were downplayed, buried in fine print, or left off the label entirely, leaving patients without the information they needed to make informed decisions.

Here's what makes this case different from the average drug lawsuit: Ozempic and its sister drugs belong to a class called GLP-1 receptor agonists, which have become among the most prescribed medications in American history. The FDA approved Ozempic for Type 2 diabetes management in 2017. By 2023, semaglutide prescriptions, driven heavily by off-label weight loss use, were being written at a rate that caused nationwide drug shortages.

That scale of use created a massive patient population exposed to the drug. When serious side effects began emerging in large numbers, attorneys took notice. So did the U.S. Judicial Panel on Multidistrict Litigation (JPML).

In simple terms, the Ozempic lawsuit alleges that Novo Nordisk prioritized market expansion over patient safety by failing to update its warning label with information about serious gastrointestinal risks as evidence accumulated over the years.

How Many People Have Sued Novo Nordisk Over Ozempic?

The numbers alone tell a significant story.

As of April 2026, more than 3,546 individual lawsuits have been filed against Novo Nordisk and are currently consolidated in MDL No. 3094 in the Eastern District of Pennsylvania. During August and September 2025 alone, plaintiff attorneys added approximately 486 new cases to the MDL, a pace that shows this litigation is still growing, not slowing down.

Now, let's put that number in context. Many of the most significant pharmaceutical mass torts in U.S. history, including the Vioxx litigation and the talcum powder cases, started with similar case counts at this stage and eventually produced billions of dollars in settlements. The Ozempic MDL is on a comparable trajectory, though no guarantees exist at this stage.

Beyond the gastrointestinal MDL, a second MDL — No. 3163 — is forming specifically to address NAION claims, which allege that semaglutide caused a rare form of vision loss called nonarteritic anterior ischemic optic neuropathy. A 2024 study published in JAMA Ophthalmology examined data from more than 37 million adults and found an association between semaglutide use and NAION, an association Novo Nordisk and Eli Lilly have disputed, but one that legal teams are citing as foundational to these claims.

The gap between filings and the actual number of affected patients may be even wider. Legal experts who handle pharmaceutical mass torts routinely point out that the majority of eligible patients never file a claim, either because they do not know the litigation exists or because they assume they cannot afford legal representation. Most Ozempic lawsuit attorneys work on a contingency fee basis, meaning no upfront cost to the client.

What Injuries Qualify for the Ozempic Lawsuit?

Not every person who experienced side effects from Ozempic will have a viable legal claim. This is where things get specific, and where people often make mistakes by self-selecting out of a claim they actually have.

The injuries currently being litigated in MDL No. 3094 and related state court cases include:

Gastrointestinal Injuries (MDL 3094)

• Gastroparesis (stomach paralysis): The digestive system's nerve and muscle function is impaired, preventing normal food processing. This is the most common and central injury alleged in these cases.

• Cyclic vomiting syndrome (CVS): Recurring episodes of severe nausea and vomiting that can be debilitating and medically complex.

• Ileus and intestinal obstruction: A condition where intestinal movement stops or is significantly blocked, sometimes requiring emergency surgical intervention.

• Pancreatitis: Inflammation of the pancreas, alleged to be linked to GLP-1 receptor agonist use.

• Gallbladder disease: Including cholecystitis and cases where gallbladder removal (cholecystectomy) was required.

• Acute kidney injury (AKI): Cases where severe dehydration from vomiting led to documented kidney damage.

Vision-Related Injuries (MDL 3163)

• NAION (Nonarteritic anterior ischemic optic neuropathy): A form of optic nerve stroke that can cause sudden and permanent vision loss. Cases are being consolidated into their own separate MDL, distinct from the gastrointestinal claims.

• Thyroid cancer and thyroid tumors: Some plaintiffs have alleged a link between semaglutide use and thyroid C-cell tumors, a risk disclosed in the existing FDA boxed warning for certain GLP-1 drugs.

• 
  

The critical point here: the injury must be medically documented. A diagnosis from a treating physician, hospitalization records, imaging studies, and gastric emptying studies (called scintigraphy) are typically the backbone of a valid claim. Cases without medical documentation face significant barriers to compensation.

Pro Tip: Even if you did not specifically receive a gastroparesis diagnosis, injuries involving documented ileus, intestinal obstruction, or repeated severe vomiting requiring hospitalization may still qualify. A mass tort attorney can review your specific medical records before you decide.

What Is MDL 3094 — and the New MDL 3163 for Vision Loss?

Two separate legal structures are handling the Ozempic and semaglutide litigation. Understanding the difference matters if you are considering filing a claim.

MDL No. 3094: The Gastrointestinal Cases

MDL No. 3094 is the primary Ozempic multidistrict litigation, currently pending before Judge Karen Spencer Marston in the Eastern District of Pennsylvania. It covers all gastrointestinal injury claims, gastroparesis, ileus, pancreatitis, gallbladder disease, and related conditions.

This MDL operates through a coordinated structure where attorneys across the country file cases in their home jurisdictions, which are then transferred and consolidated under one judge for pretrial proceedings. The goal is efficiency: rather than thousands of judges reviewing the same expert witnesses, scientific studies, and discovery documents, one court manages all of it.

The MDL structure does NOT mean all plaintiffs receive the same settlement. Each case ultimately retains its individual value based on injury severity, treatment costs, lost wages, and pain and suffering.

MDL No. 3163: The Vision Loss Cases

MDL No. 3163 was established specifically to handle NAION claims, the eye injury cases. These cases are being handled separately because the medical science involved is distinct from the gastrointestinal claims, and because the defendants include both Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound).

Previously, Judge Gene E.K. Pratter presided over portions of the early Ozempic litigation. The judge assignments in the NAION MDL and their current status should be confirmed through the court's official docket.

Feature	MDL 3094	MDL 3163
Injury Type	Gastrointestinal (gastroparesis, ileus, etc.)	Vision loss (NAION)
Location	Eastern District of Pennsylvania	Eastern District of Pennsylvania
Primary Defendants	Novo Nordisk	Novo Nordisk, Eli Lilly
Drugs Covered	Ozempic, Wegovy, Rybelsus	Ozempic, Wegovy, Mounjaro, Zepbound
Status (April 2026)	Active pretrial proceedings	Consolidation and discovery phase

Here is what most people do not realize: you do not choose which MDL your case enters. The nature of your alleged injury determines where your case is placed. A plaintiff with both gastroparesis and vision loss claims could potentially be involved in both MDLs, though this is rare.

What Is Gastroparesis and Why Is It Central to These Claims?

Gastroparesis is the medical term for delayed gastric emptying, a condition where the stomach's muscles and nerves malfunction and food no longer moves through the digestive system at a normal rate.

Gastroparesis is defined as a chronic disorder in which the stomach cannot empty itself normally in the absence of any mechanical obstruction, typically resulting in symptoms including severe nausea, vomiting, bloating, abdominal pain, and significant weight loss. It is diagnosed through a procedure called a gastric emptying study (scintigraphy), where radioactively labeled food is tracked through the stomach over a four-hour period.

Here is the crux of the legal argument: Ozempic and other semaglutide drugs work precisely by slowing gastric emptying. That mechanism is not a bug, it is the drug's intended function. It suppresses appetite and reduces blood sugar spikes by keeping food in the stomach longer. But plaintiffs and their medical experts allege that in some patients, the drug triggers a severe and permanent form of delayed emptying that meets the clinical definition of gastroparesis, long after the patient stops taking the drug.

That last part is critical. Some patients who developed gastroparesis while taking Ozempic have reportedly not recovered full stomach function even after discontinuation. That is the nature of the injury that forms the heart of these lawsuits.

Novo Nordisk's current FDA label for Ozempic does warn about nausea, vomiting, and gastrointestinal issues. The legal dispute centers on whether that warning was sufficient to alert patients and doctors to the risk of permanent gastroparesis, and whether the company had evidence of this risk earlier than the label suggests.

Gastroparesis has no reliable cure. Management involves dietary modifications, medications like metoclopramide or erythromycin, and in severe cases, surgical interventions like gastric electrical stimulation or even jejunostomy feeding tubes. The financial and quality-of-life toll can be substantial.

Ozempic NAION Lawsuits: Vision Loss Claims Explained

If you had not heard about the Ozempic vision loss claims until recently, you are not alone. This part of the litigation is newer, but it is growing quickly, and the science behind it is alarming.

NAION — non-arteritic anterior ischemic optic neuropathy. It is defined as a condition caused by a sudden reduction in blood flow to the optic nerve, resulting in acute, often irreversible vision loss in one or both eyes. It is one of the most common causes of acute optic nerve damage in adults over 50.

In 2024, researchers published a study in JAMA Ophthalmology analyzing health data from more than 37 million adults. The study found that patients prescribed semaglutide drugs had a statistically elevated risk of developing NAION compared to patients taking other diabetes or weight-loss medications. Novo Nordisk has challenged the study's methodology and disputed a causal link, emphasizing that an observational study cannot prove causation. That is the company's legal position, and it is a legitimate scientific debate.

But here is what the law requires, and this surprises many people. In a failure-to-warn case, plaintiffs do not have to prove that the drug definitively causes NAION. They need to establish that the risk was known or reasonably knowable, that it was material to a patient's decision to take the drug, and that the label failed to disclose it adequately.

Given the scale of the JAMA study and the volume of adverse event reports submitted to the FDA, plaintiff attorneys argue that Novo Nordisk had access to signals suggesting an elevated NAION risk and failed to update its labeling accordingly.

MDL No. 3163 will serve as the arena where those arguments play out.

Who Is Eligible to File an Ozempic Lawsuit?

Let's be direct about what makes someone a potential plaintiff in this litigation. Eligibility is based on three core factors:

1. Drug Use

You must have used at least one of the following semaglutide or GLP-1 receptor agonist drugs:

• Ozempic (semaglutide, Novo Nordisk) — injectable, approved for Type 2 diabetes

• Wegovy (semaglutide, Novo Nordisk) — injectable, approved for chronic weight management

• Rybelsus (semaglutide, Novo Nordisk) — oral tablet form

For vision loss (NAION) claims only, eligibility may also extend to:

• Mounjaro (tirzepatide, Eli Lilly)

• Zepbound (tirzepatide, Eli Lilly)

Note: Trulicity (dulaglutide) and Saxenda/Victoza (liraglutide) are also GLP-1 drugs but involve different manufacturers and different litigation tracks. If you used these drugs, consult with an attorney to evaluate your specific situation.

2. Medically Diagnosed Injury

You must have received a formal medical diagnosis of one of the qualifying injuries listed in the sections above. Self-diagnosis does not establish legal eligibility. You need documented medical records.

3. Causation Link

Your diagnosis must plausibly connect to the time period of your drug use. Attorneys typically look for documented symptoms that began during or shortly after use of the drug, along with records showing no pre-existing gastroparesis or NAION diagnosis before starting the medication.

A note on weight-loss use: Many patients used Ozempic off-label for weight loss, themeaning their doctor prescribed it for that purpose even though its FDA approval was for diabetes. Off-label use does not automatically disqualify you from filing a claim. What matters is documented drug use and a resulting injury.

How Much Could an Ozempic Lawsuit Settlement Be Worth?

Here is what you need to hear straight: no one can tell you with certainty what your specific Ozempic lawsuit will settle for. Anyone who promises you a specific dollar amount before reviewing your medical records is not being truthful with you.

That said, legal experts and mass tort analysts have discussed potential ranges based on injury severity, comparable pharmaceutical litigation outcomes, and the volume of plaintiffs involved. Projected liability exposure for Novo Nordisk in the Ozempic litigation has been estimated by some legal analysts at $2 billion or more across all claims, but that is a total projection, not a per-plaintiff number.

Here is a general framework attorneys use to assess case value:

Injury Severity	Estimated Settlement Range (Speculative)
Mild gastrointestinal injury, fully resolved	$50,000 to $150,000
Moderate injury requiring ongoing treatment	$150,000 to $500,000
Severe gastroparesis, permanent disability	$500,000 to $2,000,000+
NAION with significant vision loss	$500,000 to $2,500,000+
Wrongful death	$1,000,000+ (varies by state)

Important caveat: These figures are purely speculative, based on comparable pharmaceutical mass tort outcomes, and should not be taken as guarantees or predictions for any individual case. Settlement values depend on liability findings, individual damages, and the outcome of bellwether trials.

What are bellwether trials? In an MDL, the court selects a small number of representative cases, called bellwether cases, to go to trial first. These trials test the strength of both sides' arguments, reveal how juries respond, and typically catalyze global settlement negotiations. The bellwether process in MDL 3094 is underway as of 2026, making the next 12 to 24 months critically important for this litigation.

What Evidence Do You Need to File a Claim?

This is where preparation matters enormously. The strength of an Ozempic lawsuit claim depends directly on the quality and completeness of your medical documentation.

Here is what attorneys typically gather before filing:

Essential Records:

• Prescription records confirming use of Ozempic, Wegovy, or Rybelsus (pharmacy records, insurance EOB statements)

• Medical records showing the onset and diagnosis of your gastrointestinal or ophthalmic injury

• Gastric emptying study (scintigraphy) results for gastroparesis claims — this is the gold-standard diagnostic test and is frequently requested during discovery

• Hospitalization records, emergency room visits, imaging scans, and lab results

• Records from gastroenterologists, ophthalmologists, or other specialists

• Documentation of any surgeries or procedures performed as a result of the injury (e.g., gallbladder removal, gastric stimulator implantation)

Supporting Evidence:

• Timeline showing when you started the drug and when symptoms first appeared

• Documentation of all treating physicians and the treatments they recommended

• Records of lost income if your injury affected your ability to work

• Medical literature your treating physician referenced in forming your diagnosis

One thing most people overlook: Attorneys in the Ozempic MDL have noted that some plaintiffs had a prior history of mild GI issues, which Novo Nordisk's defense teams use to argue that the drug was not the cause. Attorneys recommend gathering records that clearly show a change in severity or diagnosis that correlates with semaglutide use — not just a general history of stomach problems.

Ozempic Lawsuit vs. Wegovy, Mounjaro, and Other GLP-1 Drugs

People frequently ask: is the Ozempic lawsuit the same as a Wegovy lawsuit? What about Mounjaro or Zepbound?

Here is the breakdown.

Ozempic vs. Wegovy (Novo Nordisk vs. Novo Nordisk)

Both Ozempic and Wegovy contain semaglutide and are manufactured by Novo Nordisk. The primary difference is the approved indication,, Ozempic for diabetes, Wegovy for weight management, and the dosing. For lawsuit purposes, both drugs are covered under the same manufacturer liability and both are included in MDL No. 3094.

If you took Wegovy and developed gastroparesis or a related injury, you are pursuing the same legal theory against the same defendant as an Ozempic plaintiff.

Ozempic vs. Mounjaro / Zepbound (Novo Nordisk vs. Eli Lilly)

Mounjaro and Zepbound contain tirzepatide, manufactured by Eli Lilly. While tirzepatide is also a GLP-1 receptor agonist (technically a dual GIP/GLP-1 agonist), the litigation involves a different company with a different legal exposure. Eli Lilly is named in the NAION claims in MDL No. 3163 but has its own separate legal defense strategy.

Gastrointestinal claims involving Mounjaro and Zepbound follow a similar legal theory, failure to warn, but are pursued against Eli Lilly, not Novo Nordisk.

Class Action vs. MDL: An Important Distinction

Most people search for an "Ozempic class action lawsuit", but that is not actually what exists.

The Ozempic litigation is structured as a multidistrict litigation (MDL), which is fundamentally different from a class action.

Feature	Class Action	MDL (Multidistrict Litigation)
Who receives compensation	All class members equally	Each plaintiff individually, based on their specific damages
Opt-in process	Automatic (unless you opt out)	You must actively file a claim
Settlement distribution	Divided among thousands equally	Negotiated per-plaintiff based on injury severity
Best for	Minor, widespread harms	Serious individual injuries with significant damages

The distinction matters enormously for compensation. In a class action, you might receive a small check. In an MDL, your individual settlement reflects your individual medical situation.

Novo Nordisk's Defense Strategy: What Plaintiffs Are Up Against

Let's be candid about this. Novo Nordisk is not a small company. The manufacturer of Ozempic reported revenues of approximately $44 billion in 2024,  a company with resources to mount an extremely well-funded defense.

Here is what Novo Nordisk's defense teams have generally argued:

The Label Already Warned of GI Risks

Novo Nordisk points to the existing Ozempic FDA label, which does warn of nausea, vomiting, diarrhea, and abdominal pain. The company argues this constitutes adequate warning of gastrointestinal side effects and that physicians were equipped to evaluate these risks with their patients.

Gastroparesis May Have Pre-Existing Causes

The defense strategy has consistently focused on identifying pre-existing conditions, obesity, diabetes, or other factors that independently increase gastroparesis risk. Diabetic patients — the primary Ozempic user population- already have an elevated baseline risk of gastroparesis. Distinguishing drug-induced cases from diabetes-related cases will be a central battleground in the bellwether trials.

The Science Is Not Settled

Novo Nordisk has consistently challenged the scientific evidence linking semaglutide to permanent gastroparesis and NAION, characterizing the studies as observational and insufficient to establish causation. That is a legitimate scientific argument, but it does not resolve the failure-to-warn claim, which turns on what the company knew, not just what science eventually proves.

The Preemption Defense

Some pharmaceutical defendants argue federal preemption, that because the FDA approved the label, state law failure-to-warn claims are preempted. This defense has a mixed track record in the courts and is expected to be vigorously litigated in the Ozempic MDL.

The Spencer Law Firm isis are among those actively representing plaintiffs in this litigation and are well-versed in countering these defenses.

Key Ozempic Lawsuit Updates: 2025–2026 Timeline

This is a living legal situation. Here is the most current timeline of major developments:

2017: FDA approves Ozempic for Type 2 diabetes management in the United States.

2021: Wegovy receives FDA approval for chronic weight management; semaglutide prescriptions surge.

2022–2023: Reports of severe gastrointestinal injuries in Ozempic and Wegovy users begin accumulating in FDA adverse event databases. First attorney advertisements target GI injury plaintiffs.

September 2023: The JPML consolidates gastrointestinal injury lawsuits into MDL No. 3094 in the Eastern District of Pennsylvania.

2024: A study published in JAMA Ophthalmology analyzing more than 37 million adults reports a statistically elevated association between semaglutide and NAION. Both Novo Nordisk and Eli Lilly dispute a causal link.

Late 2024: NAION-related semaglutide cases begin consolidating into MDL No. 3163, creating a second major litigation track.

August–September 2025: Approximately 486 new plaintiffs join MDL 3094 during this two-month period, signaling continued litigation growth.

April 2026: Total pending cases in MDL 3094 exceed 3,546. Bellwether case selection and scheduling orders are active. No global settlement has been announced.

Last Updated: May 2026 — This article is updated monthly to reflect the most current case counts, court orders, and settlement developments.

Frequently Asked Questions About the Ozempic Lawsuit

What is the Ozempic lawsuit about?

The Ozempic lawsuit refers to thousands of personal injury cases filed against Novo Nordisk by patients who allege that Ozempic (semaglutide) caused serious injuries — primarily gastroparesis (stomach paralysis) and vision loss (NAION) — that were not adequately disclosed on the drug's warning label. The central legal theory is failure to warn, a form of pharmaceutical product liability. As of 2026, more than 3,546 cases are consolidated in MDL No. 3094 in Pennsylvania.

How do I join the Ozempic class action lawsuit?

The Ozempic litigation is structured as a multidistrict litigation (MDL), not a traditional class action. You do not join a class — you file an individual lawsuit. To pursue a claim, contact a mass tort attorney who handles pharmaceutical product liability cases. Most offer free consultations and work on contingency fees, meaning you pay nothing unless you receive compensation.

What is MDL 3094 and how does it affect my Ozempic claim?

MDL No. 3094 is the federal multidistrict litigation consolidating gastrointestinal injury claims against Novo Nordisk in the Eastern District of Pennsylvania. If you file an Ozempic injury lawsuit related to stomach conditions, your case will likely be transferred to this MDL for pretrial coordination. Your case remains individual in terms of its value and eventual resolution.

Who qualifies to file an Ozempic lawsuit?

Generally, you may qualify if you used Ozempic, Wegovy, or Rybelsus and were subsequently diagnosed with gastroparesis, ileus, intestinal obstruction, pancreatitis, gallbladder disease, acute kidney injury, NAION, or a related serious condition. Your injury must be medically documented and plausibly connected to your period of semaglutide use. An attorney can review your specific records to assess your eligibility.

How much is the Ozempic lawsuit settlement expected to pay?

No guaranteed settlement amount exists at this stage. Legal analysts have speculated about aggregate liability in the range of $2 billion or more across all claims. Individual settlement values depend on injury severity, medical costs, lost wages, and pain and suffering. Cases involving permanent gastroparesis or significant vision loss may carry higher potential value than cases involving resolved injuries.

What is gastroparesis and how does it relate to Ozempic?

Gastroparesis is a chronic condition where the stomach's muscles and nerves fail to function normally, preventing food from emptying properly. Ozempic works by slowing gastric emptying as part of its mechanism — but plaintiffs allege this mechanism, in some users, triggered a severe and permanent form of the condition that persisted even after discontinuing the drug. Gastroparesis is diagnosed through a gastric emptying study (scintigraphy).

Is Wegovy included in the Ozempic lawsuit?

Yes. Wegovy contains the same active ingredient as Ozempic (semaglutide) and is manufactured by the same company (Novo Nordisk). Patients who developed gastroparesis or related gastrointestinal injuries while taking Wegovy can pursue claims under the same legal framework and within MDL No. 3094.

What is NAION and is it covered in the Ozempic lawsuit?

NAION stands for nonarteritic anterior ischemic optic neuropathy — a form of sudden vision loss caused by reduced blood flow to the optic nerve. A 2024 JAMA Ophthalmology study involving more than 37 million adults found a statistical association between semaglutide use and NAION. Cases alleging Ozempic or Wegovy caused vision loss are being consolidated in a separate MDL — No. 3163.

Is Mounjaro included in the GLP-1 lawsuit?

Mounjaro (tirzepatide), manufactured by Eli Lilly, is included in the NAION-related MDL (No. 3163) because it is also a GLP-1 receptor agonist implicated in the vision loss claims. For gastrointestinal claims, Mounjaro lawsuits are pursued against Eli Lilly separately from the Novo Nordisk MDL. If you used Mounjaro and suffered a serious injury, speak with an attorney about your claim against Eli Lilly.

When will the Ozempic lawsuit settle?

No timeline for global settlement has been announced as of April 2026. The bellwether trial process — where select representative cases go to trial first — is expected to inform settlement negotiations. Most large pharmaceutical MDLs resolve within three to six years of consolidation; MDL 3094 was consolidated in September 2023, placing potential resolution in the 2026–2029 window. But that is speculative. Courts and defendants negotiate on their own timelines.

What evidence do I need to file an Ozempic lawsuit?

You need prescription records confirming Ozempic, Wegovy, or Rybelsus use, medical records documenting your injury diagnosis, results from diagnostic tests (like a gastric emptying study for gastroparesis), hospitalization or treatment records, and records establishing that your injury appeared or significantly worsened during or after your drug use. An attorney will help you organize and evaluate this documentation.

Should I stop taking Ozempic if I want to file a lawsuit?

Do not stop any prescription medication without consulting your prescribing physician first. Medical decisions must be made based on your health needs, not litigation strategy. Discontinuing Ozempic abruptly without medical guidance can have serious consequences for diabetes management. Your attorney can pursue your legal claim regardless of whether you are currently taking the drug.

Conclusion: Here Is What This Means for You

The Ozempic lawsuit is one of the most consequential pharmaceutical litigations currently pending in American courts. With more than 3,546 cases in MDL 3094, a separate MDL forming around vision loss claims, and billions of dollars in projected liability, this litigation is not going away — it is accelerating.

Three things worth remembering:

The legal theory of failure to warn does not require you to prove Ozempic is a dangerous drug overall. It requires showing that Novo Nordisk knew about serious risks and did not adequately disclose them. That is a distinct and specific legal argument.

The difference between a class action and an MDL matters enormously for your compensation. This is individual litigation, meaning your settlement reflects your specific injuries and damages — not a pro-rated share of a group pool.

Evidence is everything. The strength of your claim depends on the quality of your medical documentation. Gastric emptying study results, hospitalization records, specialist diagnoses — these are what distinguish strong claims from weak ones.

If you or someone in your family used Ozempic, Wegovy, or Rybelsus and experienced severe gastrointestinal symptoms, gastroparesis, or sudden vision changes, consulting a mass tort attorney is the right first step. Most will evaluate your case at no cost and can give you an honest assessment of whether you have a viable claim.

This litigation is still developing. The decisions made in the coming 12 to 24 months, in the bellwether trials, in discovery rulings, and in settlement negotiations, will shape the compensation landscape for every plaintiff in this MDL.

Stay informed. Keep your records. And if you were seriously harmed, do not assume you have missed your window. The statute of limitations varies by state, but the litigation is still actively accepting new plaintiffs.

Legal Disclaimer: This article is for informational purposes only and does not constitute legal advice. The information presented reflects allegations made in ongoing litigation and does not represent established findings of fact or law. All references to liability are allegations that remain unproven in court. Case outcomes vary based on individual circumstances. Consult a licensed attorney for advice specific to your situation. Statistics referenced reflect publicly available case data and published research and are subject to change.

Last Updated: May 2026